Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
59 hedge funds and large institutions have $24.9M invested in Zynerba Pharmaceuticals, Inc in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 11 closing their positions.
79% more call options, than puts
Call options by funds: $215K | Put options by funds: $120K
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
5% less funds holding
Funds holding: 62 → 59 (-3)
35% less capital invested
Capital invested by funds: $38.3M → $24.9M (-$13.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$294K |
| 2 |
Two Sigma Investments
New York
|
+$194K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$161K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$150K |
| 5 |
D.E. Shaw & Co
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$2.2M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$499K |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$293K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$285K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$213K |
ZYNE Hedge Fund Activity: Q1 2022 in Review
59 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2022, worth a combined $24.9M — down 35% from $38.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ZYNE and 10 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 17 added.
The largest buyer was Vanguard Group, adding an estimated $294K. The largest seller was ETF Managers Group, cutting an estimated $2.2M.
- 59 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2022, down from 62 in Q4 2021.
- Funds reported $24.9M of Zynerba Pharmaceuticals, Inc stock for Q1 2022, down 35% quarter-over-quarter.
- 10 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2022 and 11 closed out, a net change of -1 holder.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2022 was Vanguard Group, an estimated $294K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2022 was ETF Managers Group, an estimated $2.2M sold.
Based on aggregated 13F filings for Q1 2022.